A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey
Authors:
- S DundarSDS Dundar
- B ZülfikarBZB Zülfikar
- K KavakliKKK Kavakli
- C GönenCGC Gönen
- H ZülfikarHZH Zülfikar
- D YilmazDYD Yilmaz
- Wm HartWHWm Hart
- A SümenASA Sümen
- S TunaSTS Tuna
- M KaramalisMKM Karamalis
- 1 January 2005
- journal article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 8 (1-4) , 46-54
Abstract
A decision-analysis model was constructed to assess total direct health care costs of four current first-line treatment options for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey: recombinant activated Factor VII (rFVIIa); high-dose Factor VIII; prothrombin complex concentrate (PCC); and activated PCC (aPCC). Resource utilisation was based on a retrospective analysis of 105 bleeding episodes treated during the period January 1996 to December 2002. Clinical outcomes were derived from a combination of the retrospective patient data and literature review, both validated by an expert panel of Turkish haematologists. rFVIIa was more effective and resolved bleeds more quickly than any of the alternatives. rFVIIa and PCC were associated with similar direct treatment costs that were relatively lower than those compared with the other options. Given the better efficacy, rFVIIa should be considered the preferred treatment option in the management of haemophilia patients with inhibitors in Turkey.Keywords
This publication has 13 references indexed in Scilit:
- Modelling the economic impact of recombinant activated Factor VII and activated prothrombin-complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX at a comprehensive care centre in the UKJournal of Medical Economics, 2002
- Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiencyHaemophilia, 1999
- Economic aspects of haemophilia careHaemophilia, 1999
- Le facteur VII activé recombinant: un nouveau traitement de l'hémophilieTransfusion Clinique et Biologique, 1998
- Other national modelsHaemophilia, 1998
- Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with InhibitorsThrombosis and Haemostasis, 1998
- Surgery in Hemophilia A Patients with Factor VIII Inhibitor: 10‐Year ExperienceWorld Journal of Surgery, 1996
- Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIIIThe Lancet, 1993
- Efficacy and safety of vapor‐heated anti‐inhibitor coagulant complex in hemophilia patients. FEIBA Study GroupTransfusion, 1990
- Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIIINew England Journal of Medicine, 1980